Nice work Chakay,
Here's what stands out for me:
- ARPU has a lot of room for growth as we continue to develop relationships with these businesses and move more into the corporate / custom work (not just subscription type production)
- Australia is still the core market and revenue contributions from US / Canada / UK and other markets still havent really start hitting the bottom line in a BIG way (i.e.: UK should be generating more revenue than Aus this time next year!!)
- Now that we are strongly cash flow positive, BIG's ability to invest in growth through product development (Pillar 3), acquisitions and international JV's should ensure this stays on a strong growth trajectory for the next 3 years!
- Forums
- ASX - By Stock
- BIG
- BIG - Peer Comparisons Valuations
BIG - Peer Comparisons Valuations, page-2
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online